Guardian Pharmacy Services (NYSE:GRDN) Issues Earnings Results

Guardian Pharmacy Services (NYSE:GRDN) issued its quarterly earnings data on Thursday. The company reported $0.29 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.26 by $0.03, FiscalAI reports. Guardian Pharmacy Services had a net margin of 4.50% and a return on equity of 31.45%. The firm had revenue of $351.77 million for the quarter, compared to analyst estimates of $340.45 million.

Here are the key takeaways from Guardian Pharmacy Services’ conference call:

• Guardian raised its 2026 outlook, now expecting revenue of $1.43 billion–$1.45 billion and adjusted EBITDA of $129 million–$131 million, up from prior ranges of $1.40 billion–$1.42 billion and $123 million–$127 million, respectively.
• Second-quarter adjusted EBITDA increased 19% to $29.7 million, supported by an 18% increase in gross profit, favorable product and payer mix, purchasing leverage, labor productivity, and operating efficiencies.
• The company reported continued operating expansion, including high-single-digit growth in residents served and script volumes, the acquisition of Wellness Concepts in Virginia, and the launch of a greenfield pharmacy in Lexington, Kentucky.
• Guardian said IRA-related pricing reductions will continue to pressure reported revenue, with second-half revenue expected to decline year over year by a low-single-digit percentage; management expects underlying revenue growth to remain in the high-single digits and believes the margin impact has been mitigated.
• Approximately 13.5 million Class B shares are expected to convert into Class A shares in late September, and 35 million–37 million employee, management, and director-held Class A shares could become eligible for sale after the next trading window following the third-quarter results, creating a potential supply overhang.

Guardian Pharmacy Services Trading Up 9.8%

Shares of GRDN stock traded up $3.88 during mid-day trading on Friday, reaching $43.35. The stock had a trading volume of 1,045,061 shares, compared to its average volume of 277,924. The company has a market cap of $2.16 billion, a P/E ratio of 42.09, a price-to-earnings-growth ratio of 2.59 and a beta of 0.10. Guardian Pharmacy Services has a 12-month low of $19.30 and a 12-month high of $47.02. The business has a 50-day simple moving average of $40.93 and a 200 day simple moving average of $37.09.

Analysts Set New Price Targets

A number of research analysts have commented on GRDN shares. Oppenheimer upped their price target on Guardian Pharmacy Services from $43.00 to $49.00 and gave the stock an “outperform” rating in a research note on Friday. Truist Financial boosted their price target on shares of Guardian Pharmacy Services from $43.00 to $47.00 and gave the stock a “buy” rating in a report on Wednesday, June 17th. Bank of America increased their price objective on Guardian Pharmacy Services from $42.00 to $47.00 and gave the company a “buy” rating in a report on Wednesday, June 17th. Wall Street Zen downgraded Guardian Pharmacy Services from a “buy” rating to a “hold” rating in a report on Saturday, August 1st. Finally, Weiss Ratings upgraded shares of Guardian Pharmacy Services from a “hold (c)” rating to a “hold (c+)” rating in a research note on Thursday. Seven investment analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $43.83.

Institutional Inflows and Outflows

Institutional investors have recently modified their holdings of the stock. Dynamic Technology Lab Private Ltd purchased a new position in Guardian Pharmacy Services during the first quarter worth $233,000. JPMorgan Chase & Co. lifted its position in shares of Guardian Pharmacy Services by 48.0% in the second quarter. JPMorgan Chase & Co. now owns 6,027 shares of the company’s stock valued at $128,000 after acquiring an additional 1,956 shares in the last quarter. Legal & General Group Plc boosted its stake in shares of Guardian Pharmacy Services by 1,783.1% during the second quarter. Legal & General Group Plc now owns 14,895 shares of the company’s stock valued at $317,000 after acquiring an additional 14,104 shares during the last quarter. Rhumbline Advisers boosted its stake in shares of Guardian Pharmacy Services by 121.1% during the second quarter. Rhumbline Advisers now owns 16,174 shares of the company’s stock valued at $345,000 after acquiring an additional 8,860 shares during the last quarter. Finally, Quantbot Technologies LP purchased a new stake in Guardian Pharmacy Services during the 2nd quarter worth about $214,000.

Guardian Pharmacy Services Company Profile

Guardian Pharmacy Services, Inc, a pharmacy service company, provides a suite of technology-enabled services designed to help residents of long-term health care facilities (LTCFs) in the United States. Its individualized clinical, drug dispensing, and administration capabilities are used to serve the needs of residents in lower acuity LTCFs, such as assisted living facilities and behavioral health facilities and group homes. The company’s Guardian Compass includes dashboards created using data from its data warehouse to help its local pharmacies plan, track, and optimize their business operations; and GuardianShield Programs for LTCFs.